Conference LibraryGated
Bone Marrow Transplant 2026 · Bridging therapy before anti-BCMA CAR-T · Rasche/Raab
"Use of anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy to treat relapsed/refractory multiple myeloma is increasing. Studies suggest that effective bridging therapy (BT) prior to anti-BCMA CAR-T therapy can enhance efficacy and safety outco…
- Type
- paper
- Domain
- oncology
- Grade
- conference
- License
- LIGHT_HOPE_proprietary
- Provenance
- m622_verify_wave_2_2026-05-16
- evidence_grade
- A
- category
- bcma_car_t_clinical_workflow
- status
- verified
- instance_tag
- sunvax-antibody-2025
- clinical_claim_softening
- "expert panel consensus · ex vivo BCMA CAR-T workflow context · not intended to guide individual patient treatment choices · in vivo BCMA CAR-T (ESO-T01 etc) sits separately"
- journal
- Bone Marrow Transplantation
- year
- 2026
- authors
- Leo Rasche,Marc S Raab
- abstract_snippet
- "Use of anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy to treat relapsed/refractory multiple myeloma is increasing. Studies suggest that effective bridging therapy (BT) prior to anti-BCMA CAR-T therapy can enhance efficacy and safety out
- pmid
- 42129310
- doi
- 10.1038/s41409-026-02905-1
Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.